Articles by Brian G. Feagan

1 2 3 4 5

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease

Sandborn, William J.; Wolf, Douglas C.; Kosutic, Gordana; More

Inflammatory Bowel Diseases. 23(7):1047-1056, July 2017.

Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases

Ghosh, Subrata; Sandborn, William J.; Colombel, Jean-Frederic; More

Inflammatory Bowel Diseases. 22(11):2711-2723, November 2016.

The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews

Khanna, Reena; Chande, Nilesh; Vermeire, Séverine; More

Inflammatory Bowel Diseases. 22(7):1737-1743, July 2016.

New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?

Chande, Nilesh; Marshall, John K.; Seow, Cynthia H.; More

Inflammatory Bowel Diseases. 21(12):2948-2957, December 2015.

Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial

Panaccione, Remo; Sandborn, William J.; Gordon, Glenn L.; More

Inflammatory Bowel Diseases. 21(6):1329-1340, June 2015.

Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis

Mosli, Mahmoud H.; MacDonald, John K.; Bickston, Stephen J.; More

Inflammatory Bowel Diseases. 21(5):1151-1159, May 2015.

Assessment of Histologic Disease Activity in Crohn's Disease: A Systematic Review

Mojtahed, Amirkaveh; Khanna, Reena; Sandborn, William J.; More

Inflammatory Bowel Diseases. 20(11):2092-2103, November 2014.

Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?

Akobeng, Anthony A.; Sandborn, William J.; Bickston, Stephen J.; More

Inflammatory Bowel Diseases. 20(11):2132-2141, November 2014.

A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease: Recommendations for Clinical Trial Design

Khanna, Reena; Bouguen, Guillaume; Feagan, Brian G.; More

Inflammatory Bowel Diseases. 20(10):1850-1861, October 2014.

A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research

Samaan, Mark A.; Mosli, Mahmoud H.; Sandborn, William J.; More

Inflammatory Bowel Diseases. 20(8):1465-1471, August 2014.

Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices

Mosli, Mahmoud H.; Feagan, Brian G.; Sandborn, William J.; More

Inflammatory Bowel Diseases. 20(3):564-575, March 2014.

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

Reinisch, Walter; Sandborn, William J.; Rutgeerts, Paul; More

Inflammatory Bowel Diseases. 18(2):201-211, February 2012.

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

Feagan, Brian G.; Lémann, Marc; Befrits, Ragnar; More

Inflammatory Bowel Diseases. 18(1):152-160, January 2012.

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

D'Haens, Geert R.; Fedorak, Richard; Lémann, Marc; More

Inflammatory Bowel Diseases. 15(10):1599-1604, October 2009.

Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis

Reinisch, Walter; Sandborn, William J.; Bala, Mohan; More

Inflammatory Bowel Diseases. 13(9):1135-1140, September 2007.

1 2 3 4 5